Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
-0.26% $30.37
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 13 566 mill |
EPS: | 2.53 |
P/E: | 12.00 |
Earnings Date: | May 06, 2024 |
SharesOutstanding: | 446.69 mill |
Avg Daily Volume: | 2.66 mill |
RATING 2024-03-28 |
---|
S |
Strong Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Buy | |
Return On Asset: | Strong Buy | |
DE: | Strong Buy | |
P/E: | Strong Buy | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 12.00 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
2.04x |
Company: PE 12.00 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$78.90 (159.81%) $48.53 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 29.66 - 31.08 ( +/- 2.34%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-20 | Riggs Rory B | Buy | 300 000 | Class A Ordinary Shares |
2024-02-20 | Riggs Rory B | Sell | 30 000 | LP interests in RPI US Partners 2019, LP |
2024-01-02 | Riggs Rory B | Sell | 235 200 | Class A Ordinary Shares |
2024-01-03 | Riggs Rory B | Sell | 199 098 | Class A Ordinary Shares |
2024-01-04 | Riggs Rory B | Sell | 35 702 | Class A Ordinary Shares |
INSIDER POWER |
---|
-37.16 |
Last 100 transactions |
Buy: 3 305 882 | Sell: 7 663 240 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $30.37 (-0.26% ) |
Volume | 2.71 mill |
Avg. Vol. | 2.66 mill |
% of Avg. Vol | 102.06 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $28.55 | N/A | Active |
---|
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.